In the BioHarmony Drug Report Database
Darolutamide
Nubeqa (darolutamide) is a small molecule pharmaceutical. Darolutamide was first approved as Nubeqa on 2019-07-30. It has been approved in Europe to treat castration-resistant prostatic neoplasms. The pharmaceutical is active against androgen receptor. Nubeqa’s patent is valid until 2036-01-28 (FDA).
Trade Name
|
Nubeqa |
|---|---|
Common Name
|
darolutamide |
ChEMBL ID
|
CHEMBL4297185 |
Indication
|
castration-resistant prostatic neoplasms |
Drug Class
|
Non-steroid antiandrogens |
Image (chem structure or protein)